Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient

Submitted: January 1, 2019
Accepted: May 12, 2019
Published: May 30, 2019
Abstract Views: 1256
PDF: 766
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Lung cancer incidence in heart transplant patients is higher than in general population and correlates with smoking history. EGFR-mutations are more frequent in adenocarcinoma and among non-smoking women but incidence in solid organ transplanted patients is still not known. We present case of a 65-year-old ex-smoker male with history of heart transplantation and EGFR positive metastatic lung adenocarcinoma. At admission he was in a severe clinical condition and treatment with erlotinib was started. Initially he had good clinical and radiologic response to treatment with only grade 1 side effects.  Data about drug interactions between cyclosporine and erlotinib are insufficient but we have to take this interaction into consideration during treatment because both drugs are substrates and inhibitors of CYP34A. In our case erlotinib was safe and well tolerated drug, there were no relevant toxicity, but close monitoring and dose reduction of cyclosporine was needed.



PlumX Metrics


Download data is not yet available.


How to Cite

Hecimovic, Ana, Andrea Vukic Dugac, Mateja Jankovic Makek, Maja Cikes, Miroslav Samarzija, and Marko Jakopovic. 2019. “Treatment of EGFR Positive Lung Adenocarcinoma in a Heart Transplanted Patient”. Monaldi Archives for Chest Disease 89 (2).